Australia | Part 2: Regulatory considerations for orphan drugs
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets out the key regulatory considerations in Australia. Orphan drug patent strategy...
Following our first article on orphan drug development, which examined key patenting options and strategies, our second article sets...
Read More
Full Court finds that usual undertaking for damages is not limited by TG Act
The fact that the Therapeutic Goods Act 1989 contains provisions that permit the Commonwealth, among other parties, to recover compensation in certain pharmaceutical patent infringement proceedings does not preclude...
The fact that the Therapeutic Goods Act 1989 contains provisions that permit the Commonwealth, among other parties, to recover...
Read More